SAN.PA: Summary for SANOFI - Yahoo Finance

UK Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed price. Currency in EUR
Add to watchlist
84.24-0.27 (-0.32%)
At close: 5:37PM CEST
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close84.51
Open84.50
Bid71.12 x 1000
Ask71.74 x 44000
Day's range83.48 - 84.67
52-week range62.50 - 84.93
Volume1,702,510
Avg. volume2,278,309
Market cap105.9B
Beta0.74
PE ratio (TTM)23.19
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield3.35 (3.69%)
Ex-dividend dateN/A
1y target estN/A
  • Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster
    Motley Fool5 hours ago

    Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

    The FDA has approved Dupixent for moderate to severe eczema, making it the first non-topical drug to win regulatory support in the indication.

  • American City Business Journalsyesterday

    Sanofi Genzyme files preemptive legal strike to protect eczema drug

    Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (AMGN).

  • Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
    Zacksyesterday

    Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

    Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).